CRISPR Therapeutics proved the strength of its technology a couple of years ago when it won approval for its first product.

India has developed BIRSA 101, its first indigenous CRISPR gene therapy for sickle cell disease, using a more precise ...

With Phase 3 data in hand, Intellia Therapeutics is seeking approval for its in vivo CRISPR gene editing therapy for ...

The company's treatment for hereditary angioedema reduced attacks by 87% vs. placebo in a Phase 3 trial, clearing the way for ...

IDT played a pivotal role in manufacturing the personalized gene editing therapy given to baby KJ Muldoon to treat his rare ...

Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities possible for the new generation of genetic medicines.

Following the rise in Mpox cases, particularly in countries where the disease had not traditionally been observed, the World ...

Intellia also separately announced positive topline data today from the Phase 3 HAELO clinical trial of lonvo-z in HAE. The trial met its primary and all key secondary endpoints, demonstrating that a ...

The U.S. FDA has begun piloting real-time clinical trial tracking in two cancer studies to speed up safety and efficacy monitoring. The move comes as CRISPR Therapeutics attracts investor attention ...

Study discover that evolution reuses same genes to create identical wing patterns in butterflies and moths separated by 120 ...

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the ...